Signal Transduction and Targeted Therapy (Mar 2023)

PMN-MDSCs modulated by CCL20 from cancer cells promoted breast cancer cell stemness through CXCL2-CXCR2 pathway

  • Rui Zhang,
  • Mengxue Dong,
  • Juchuanli Tu,
  • Fengkai Li,
  • Qiaodan Deng,
  • Jiahui Xu,
  • Xueyan He,
  • Jiajun Ding,
  • Jie Xia,
  • Dandan Sheng,
  • Zhaoxia Chang,
  • Wei Ma,
  • Haonan Dong,
  • Yi Zhang,
  • Lixing Zhang,
  • Lu Zhang,
  • Suling Liu

DOI
https://doi.org/10.1038/s41392-023-01337-3
Journal volume & issue
Vol. 8, no. 1
pp. 1 – 14

Abstract

Read online

Abstract Our previous studies have showed that C-C motif chemokine ligand 20 (CCL20) advanced tumor progression and enhanced the chemoresistance of cancer cells by positively regulating breast cancer stem cell (BCSC) self-renewal. However, it is unclear whether CCL20 affects breast cancer progression by remodeling the tumor microenvironment (TME). Here, we observed that polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs) were remarkably enriched in TME of CCL20-overexpressing cancer cell orthotopic allograft tumors. Mechanistically, CCL20 activated the differentiation of granulocyte-monocyte progenitors (GMPs) via its receptor C-C motif chemokine receptor 6 (CCR6) leading to the PMN-MDSC expansion. PMN-MDSCs from CCL20-overexpressing cell orthotopic allograft tumors (CCL20-modulated PMN-MDSCs) secreted amounts of C-X-C motif chemokine ligand 2 (CXCL2) and increased ALDH+ BCSCs via activating CXCR2/NOTCH1/HEY1 signaling pathway. Furthermore, C-X-C motif chemokine receptor 2 (CXCR2) antagonist SB225002 enhanced the docetaxel (DTX) effects on tumor growth by decreasing BCSCs in CCL20high-expressing tumors. These findings elucidated how CCL20 modulated the TME to promote cancer development, indicating a new therapeutic strategy by interfering with the interaction between PMN-MDSCs and BCSCs in breast cancer, especially in CCL20high-expressing breast cancer.